You are here



NorDiag continues to expand its portfolio of unique sample preparation kits. Today the company announces together with Molzym the launch of selectNA(TM) ultra sensitive pathogen detection system.
As infectious diseases and antibiotic resistances have dramatically increased in recent years, there is strong demand in the market for rapid, sensitive, culture-independent identification and susceptibility testing products. Automation of diagnostic workflows will lower costs and improve the speed of the diagnosis making.
SelectNA(TM) is a unique automated sample preparation system for pathogen identification directly from blood. The platform consists of NorDiag's Arrow instrument and Molzym's MolYsis reagents for ultra-sensitive, pathogen-specific DNA isolation.
The groundbreaking selectNA(TM) allows for up to 40,000-fold better PCR sensitivity as compared to conventional DNA-isolation protocols. The system therefore enables culture-independent direct testing of a number of sterile body fluids and tissues. It supports Molzym's stand alone SepsiTest(TM) for detection and identification of culture negative blood stream infections and it may be combined with any molecular pathogen identification assays, e.g. SepsiTest(TM) (Molzym) or antibiotic resistance assays, e.g. MRSA, Vancomycin and ESBL assays from various suppliers on a variety technology platforms.  
"Our collaboration with Molzym is taking its form and selectNA(TM) is a strong addition to our product portfolio. The system will now be sold by NorDiag in Nordic countries and US, and by Molzym's distributors in other countries. Part of the strategy will also be to enter into OEM agreements with assays providers", explains Mårten Wigstøl, CEO in NorDiag.
"After evaluating a range of platforms in the market, we decided for NorDiag, because of their absolutely DNA-free automation platform. The Arrow instrument currently is the only automation system on the market using a tubing-free and 100% contamination-safe pipetting technology", explains Dr. Jan Detmers, CEO in Molzym. "We estimate the molecular based target market to be in the range of USD 150 - 200 million", he adds.
CEO Mårten Wigstøl, Phone. +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 35.3 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.
For further information -
About Molzym:
Molzym GmbH & Co. KG, headquartered in Bremen, Germany, is a manufacturer of innovative products for molecular diagnostics. Based on proprietary, patented technologies Molzym's kits and molecular diagnostic tools focus on the selective isolation of pathogen DNA from whole blood, robust and contamination-free PCRreagents and the molecular detection and identification of bacteria and fungi. For more than 5 years, the world market of molecular diagnostics shows a compound annual growth rate of about 15%. Molzym regards itself as the technology and market leader in broad-spectrum molecular diagnostics. This market is believed to be one of the most important growth markets in diagnostics because of emerging infectious diseases and increasing antibiotic resistances around the world. For further information -
Press contact:
CEO Dr. Jan Detmers, Phone: +49 421-696162-0 E-mail:

Read the notice in Norwegian here.